Molecular biomarkers of neurodegeneration

Expert Rev Mol Diagn. 2013 Nov;13(8):845-61. doi: 10.1586/14737159.2013.850033.

Abstract

Neuronal dysfunction and degeneration are central events of a number of major diseases with significant unmet need. Neuronal dysfunction may not necessarily be the result of cell death, but may also be due to synaptic damage leading to impaired neuronal cell signaling or long-term potentiation. Once degeneration occurs, it is unclear whether axonal or synaptic loss comes first or whether this precedes neuronal cell death. In this review we summarize the pathophysiology of four major neurodegenerative diseases; Alzheimer's disease, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis (Lou Gehrig's disease) For each of these diseases, we describe how biochemical biomarkers are currently understood in relation to the pathophysiology and in terms of neuronal biology, and we discuss the clinical and diagnostic utility of these potential tools, which are at present limited. We discuss how markers may be used to drive drug development and clinical practice.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / diagnosis*
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / pathology
  • Amyotrophic Lateral Sclerosis / diagnosis*
  • Amyotrophic Lateral Sclerosis / metabolism
  • Amyotrophic Lateral Sclerosis / pathology
  • Biomarkers / metabolism
  • Clinical Trials as Topic
  • Humans
  • Multiple Sclerosis / diagnosis*
  • Multiple Sclerosis / metabolism
  • Multiple Sclerosis / pathology
  • Nerve Tissue Proteins / metabolism*
  • Neurons / metabolism
  • Neurons / pathology
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology

Substances

  • Biomarkers
  • Nerve Tissue Proteins